These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18762759)

  • 21. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.
    Vesole DH; Simic A; Lazarus HM
    Bone Marrow Transplant; 2001 Oct; 28(8):725-35. PubMed ID: 11781623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
    Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA
    Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma.
    Björkstrand B; Ljungman P; Bird JM; Samson D; Gahrton G
    Bone Marrow Transplant; 1995 Mar; 15(3):367-71. PubMed ID: 7599560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous blood progenitor cell transplantation in high-risk multiple myeloma.
    Marit G; Fabères C; Boiron JM; Fourès C; Puntous M; Cony-Makhoul P; Bernard P; Merlet M; Lorin JC; Ceccaldi J
    Stem Cells; 1995 Aug; 13 Suppl 2():160-3. PubMed ID: 8520506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spontaneous graft versus host disease occurring in a patient with multiple myeloma after autologous stem cell transplant.
    Fidler C; Klumpp T; Mangan K; Martin M; Sharma M; Emmons R; Lu M; Kropf P
    Am J Hematol; 2012 Feb; 87(2):219-21. PubMed ID: 22189875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
    Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
    Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of cyclosporin A-induced autologous graft-versus-host disease after peripheral blood stem cell transplantation by utilizing selected CD34(+) cells.
    Miura Y; Ueda M; Takami A; Shiobara S; Nakao S; Hess AD
    Bone Marrow Transplant; 2003 Oct; 32(8):785-90. PubMed ID: 14520422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of autologous blood stem cells in support of high-dose therapy for multiple myeloma.
    Fermand JP; Chevret S; Levy Y; Miclea JM; Tsapis A; Gerota J; Benbunan M; Brouet JC
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):451-62. PubMed ID: 1349886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Tandem transplantation with peripheral autologous hematopoietic blood stem cells in treatment of oncologic and hematologic malignancies. Initial results of the Donauspital, Vienna].
    Ruckser R; Kier P; Sebesta C; Kittl E; Kurz M; Selleny S; Höniger S; Scherz M; Habertheuer KH; Zelenka P
    Wien Med Wochenschr; 1995; 145(2-3):41-4, 46-7. PubMed ID: 7762251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
    El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
    Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma.
    Alici E; Björkstrand B; Treschow A; Aints A; Smith CI; Gahrton G; Dilber MS
    Cancer Gene Ther; 2007 Mar; 14(3):227-32. PubMed ID: 17082794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation.
    Sevilla J; Rodríguez A; Hernández-Maraver D; de Bustos G; Aguado J; Ojeda E; Arrieta R; Hernández-Navarro F
    Ann Hematol; 2002 Jan; 81(1):11-5. PubMed ID: 11807629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
    Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
    Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.